NASDAQ:PRAX - Praxis Precision Medicines Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 246.15 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.60
▲ +0.09 (3.59%)

This chart shows the closing price for PRAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Praxis Precision Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRAX

Analyst Price Target is $9.00
▲ +246.15% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Praxis Precision Medicines in the last 3 months. The average price target is $9.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 246.15% upside from the last price of $2.60.

This chart shows the closing price for PRAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Praxis Precision Medicines. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2022Piper SandlerLower Price TargetOverweight$65.00 ➝ $18.00Low
6/7/2022Bank of AmericaDowngradeBuy ➝ Neutral$4.00Low
6/7/2022HC WainwrightLower Price TargetBuy$48.00 ➝ $10.00Low
6/6/2022WedbushDowngradeOutperform ➝ Neutral$4.00N/A
5/10/2022WedbushLower Price Target$40.00 ➝ $34.00High
12/16/2021HC WainwrightInitiated CoverageBuy$48.00Low
11/4/2021WedbushLower Price TargetOutperform$50.00 ➝ $45.00Medium
8/26/2021Bank of AmericaInitiated CoverageBuy$28.00Low
5/3/2021William BlairInitiated CoverageOutperformMedium
4/26/2021William BlairInitiated CoverageOutperformHigh
1/21/2021WedbushBoost Price TargetOutperform$51.00 ➝ $61.00Medium
11/11/2020WedbushInitiated CoverageOutperform$40.00High
11/10/2020Evercore ISIInitiated CoverageOutperform$55.00High
11/10/2020CowenInitiated CoverageOutperformHigh
11/10/2020Piper SandlerInitiated CoverageOverweight$65.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

-0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/6/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/6/2022
  • 6 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/5/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
7/5/2022

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
Praxis Precision Medicines logo
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $2.60
Low: $2.42
High: $2.62

50 Day Range

MA: $6.07
Low: $1.75
High: $10.95

52 Week Range

Now: $2.60
Low: $1.63
High: $23.56

Volume

1,090,301 shs

Average Volume

920,074 shs

Market Capitalization

$118.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Praxis Precision Medicines?

The following Wall Street analysts have issued research reports on Praxis Precision Medicines in the last year: Bank of America Co., HC Wainwright, Piper Sandler, and Wedbush.
View the latest analyst ratings for PRAX.

What is the current price target for Praxis Precision Medicines?

0 Wall Street analysts have set twelve-month price targets for Praxis Precision Medicines in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 246.2%.
View the latest price targets for PRAX.

What is the current consensus analyst rating for Praxis Precision Medicines?

Praxis Precision Medicines currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRAX will outperform the market and that investors should add to their positions of Praxis Precision Medicines.
View the latest ratings for PRAX.

How do I contact Praxis Precision Medicines' investor relations team?

Praxis Precision Medicines' physical mailing address is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. The company's listed phone number is 617-300-8460 and its investor relations email address is [email protected] The official website for Praxis Precision Medicines is www.praxismedicines.com. Learn More about contacing Praxis Precision Medicines investor relations.